xRead - September 2022

Wise et al.

Page 366

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion

Horak et al. 1046 2006 1b DBRCT 1 Azelastine 0.4 mg daily; TNSS Azelastine superior to desloratadine and placebo. Corren et al. 1217 2005 1b DBRCT 1 Azelastine 0.56 mg BID; 2 Desloratadine 5-mg tablet daily; 3 Placebo spray

2 Cetirizine 10-mg tablet daily TNSS, RQLQ Azelastine superior cetirizine for symptoms and QOL. Meltzer et al. 1218 2005 1b DBRCT 1 Olopatadine 2.66 mg BID; 2 Olopatadine 1.77 mg BID; 3 Placebo

TNSS, RQLQ Olopatadine (both doses) superior to placebo for symptoms and QOL improvement.

TNSS Olopatadine (both doses) superior to placebo.

LaForce et al. 1220 2004 1b DBRCT 1 Azelastine 0.56 mg BID; 2 Azelastine 0.56 mg BID + fexofenadine 60-mg tablet BID; 3 Placebo spray + placebo tablet TNSS Azelastine superior to placebo; no additional benefit of adding oral fexofenadine to azelastine monotherapy. Berger & White 1221 2003 1b DBRCT 1 Azelastine 0.56 mg BID; TNSS All treatments superior to placebo; azelastine at least as effective as

desloratadine; no additional benefit of adding oral loratadine to azelastine monotherapy.

Azelastine superior to placebo for symptoms; no effect on nasal eosinophils or cytokines; azelastine inhibits methacholine response. Azelastine superior to levocabastine.

9-item symptom score Flunisolide superior to azelastine; both treatments superior to placebo.

TNSS, nasal lavage,

methacholine challenge

10-item symptom score, global assessment

Ratner et al. 1219 2005 1b DBRCT 1 Olopatadine 2.66 mg BID;

2 Olopatadine 1.77 mg BID; 3 Placebo

2 Azelastine 0.56 mg BID + loratadine 10-mg tablet;

3 Desloratadine 5-mg tablet + placebo spray; 4 Placebo spray + placebo tablet

Saengpanich et al. 1222 2002 1b DBRCT 1 Azelastine 0.28 mg BID; 2 Placebo

Falser et al. 1223 2001 1b DBRCT 1 Azelastine 0.56 mg BID;

2 Levocabastine 0.2 mg spray BID Berlin et al. 1224 2000 1b DBRCT 1 Azelastine 0.56 mg BID;

2 Flunisolide 0.116 mg spray BID;

Study Year LOE

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.